79 related articles for article (PubMed ID: 3509385)
21. Bacteraemia in a tertiary care urban hospital in south India.
Chaudhury A; Rao TV
Indian J Pathol Microbiol; 1999 Jul; 42(3):317-20. PubMed ID: 10862291
[TBL] [Abstract][Full Text] [Related]
22. Comparative in vitro activity of imipenem and nine other antimicrobials against recently isolated pathogens.
Bonadio M; Maccanti O; Cosci S; Giordani R
J Chemother; 1989 Jul; 1(4 Suppl):58-60. PubMed ID: 16312303
[No Abstract] [Full Text] [Related]
23. Antimicrobial activity of enoxacin.
Nicoletti G; Caccamo F; Speciale A
J Chemother; 1989 Jul; 1(4 Suppl):143-4. PubMed ID: 16312344
[No Abstract] [Full Text] [Related]
24. In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent.
Kwon AR; Min YH; Ryu JM; Choi DR; Shim MJ; Choi EC
J Antimicrob Chemother; 2006 Sep; 58(3):684-8. PubMed ID: 16873394
[TBL] [Abstract][Full Text] [Related]
25. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis.
Alhanout K; Brunel JM; Raoult D; Rolain JM
J Antimicrob Chemother; 2009 Oct; 64(4):810-4. PubMed ID: 19666647
[TBL] [Abstract][Full Text] [Related]
26. Antibacterial activity of Acalypha indica L.
Govindarajan M; Jebanesan A; Reetha D; Amsath R; Pushpanathan T; Samidurai K
Eur Rev Med Pharmacol Sci; 2008; 12(5):299-302. PubMed ID: 19024213
[TBL] [Abstract][Full Text] [Related]
27. In vitro comparison of ciprofloxacin to parenteral antibiotics.
Speciale A; Caccamo F; Nicoletti G
J Chemother; 1989 Jul; 1(4 Suppl):154-6. PubMed ID: 16312349
[No Abstract] [Full Text] [Related]
28. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
Hoban DJ; Bouchillon SK; Johnson BM; Johnson JL; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):215-27. PubMed ID: 16105567
[TBL] [Abstract][Full Text] [Related]
29. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
[TBL] [Abstract][Full Text] [Related]
30. [Evolution of bacterial species and their sensitivity to antibiotics in the laboratory of a small hospital].
Laurent A; Berger JP
Rev Med Suisse Romande; 1996 Feb; 116(2):125-30. PubMed ID: 8701198
[No Abstract] [Full Text] [Related]
31. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
Barry AL; Fuchs PC; Brown SD
Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and antibacterial activity of quinolone-based compounds containing a coumarin moiety.
Emami S; Foroumadi A; Faramarzi MA; Samadi N
Arch Pharm (Weinheim); 2008 Jan; 341(1):42-8. PubMed ID: 18072241
[TBL] [Abstract][Full Text] [Related]
33. In vitro activity of faropenem compared with eight agents against fourteen Gram-positive and Gram-negative bacteria by time-kill.
Credito KL; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 2003 Jun; 51(6):1437-9. PubMed ID: 12746376
[No Abstract] [Full Text] [Related]
34. [In vitro evaluation of norfloxacin on clinically isolated bacterial strains].
Chiaradia V; Romeo AA; Pascoli L; Santini G
Nuovi Ann Ig Microbiol; 1984; 35(6):471-81. PubMed ID: 6545701
[No Abstract] [Full Text] [Related]
35. [Antibacterial activity of mezlocillin against gram-negative and gram-positive bacteria from clinical isolates].
Ravizzola G; Foresti I; Minelli F
G Ital Chemioter; 1985; 32(2):277-80. PubMed ID: 3833562
[No Abstract] [Full Text] [Related]
36. Synthesis and antibacterial activity of N-[2-(5-bromothiophen-2-yl)-2-oxoethyl] and N-[(2-5-bromothiophen-2-yl)-2-oximinoethyl] derivatives of piperazinyl quinolones.
Foroumadi A; Emami S; Mehni M; Moshafi MH; Shafiee A
Bioorg Med Chem Lett; 2005 Oct; 15(20):4536-9. PubMed ID: 16115766
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the in vitro susceptibility of rifaximin versus norfloxacin against multidrug resistant bacteria in a hospital setting. A proof-of-concept study for use in advanced cirrhosis.
Ramos JM; Vidal I; Bellot P; Gómez-Hurtado I; Zapater P; Such J
Gut; 2016 Jan; 65(1):182-3. PubMed ID: 25832107
[No Abstract] [Full Text] [Related]
38. Studies on prodrugs. 11. Synthesis and antimicrobial activity of N-[(4-methyl-5-methylene-2-oxo-1,3-dioxolan-4-yl)oxy]norfloxacin .
Kondo H; Sakamoto F; Uno T; Kawahata Y; Tsukamoto G
J Med Chem; 1989 Mar; 32(3):671-4. PubMed ID: 2645402
[TBL] [Abstract][Full Text] [Related]
39. Antibacterial activity of norfloxacin against bacterial isolates from the urinary tract.
Qadri SM; Johnson S
J Natl Med Assoc; 1989 Apr; 81(4):382-5. PubMed ID: 2738947
[TBL] [Abstract][Full Text] [Related]
40. Methyloxime-substituted aminopyrrolidine: a new surrogate for 7-basic group of quinolone.
Hong CY; Kim YK; Lee YH; Kwak JH
Bioorg Med Chem Lett; 1998 Feb; 8(3):221-6. PubMed ID: 9871658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
